139 related articles for article (PubMed ID: 37170775)
1. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Kum YE; Pamukçu Ö; Canpolat M
Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
Petruzzo M; Lanzillo R
Neurol Sci; 2021 May; 42(Suppl 1):37-39. PubMed ID: 33635428
[TBL] [Abstract][Full Text] [Related]
3. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
[TBL] [Abstract][Full Text] [Related]
4. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
[TBL] [Abstract][Full Text] [Related]
5. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
[TBL] [Abstract][Full Text] [Related]
6. Mobitz type I and II atrioventricular blocks during fingolimod therapy.
Saccà F; Puorro G; Marsili A; Pane C; Russo CV; Lanzillo R; de Rosa A; Cittadini A; De Angelis G; Brescia Morra V
Neurol Sci; 2016 Sep; 37(9):1557-9. PubMed ID: 27225279
[TBL] [Abstract][Full Text] [Related]
7. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
Feige J; Schernthaner C; Wipfler P; Sellner J
Mult Scler Relat Disord; 2020 Feb; 38():101515. PubMed ID: 31751857
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
9. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
[TBL] [Abstract][Full Text] [Related]
10. Vagomimetic effects of fingolimod: physiology and clinical implications.
Vanoli E; Pentimalli F; Botto G
CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
[TBL] [Abstract][Full Text] [Related]
11. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
Datt J; Baldock L; Pull E; Webber B
Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Voon V; Saiva L; O'Kelly S; Keane D
Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
[No Abstract] [Full Text] [Related]
13. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
Laroni A; Brogi D; Morra VB; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL;
BMC Neurol; 2014 Apr; 14():65. PubMed ID: 24690227
[TBL] [Abstract][Full Text] [Related]
14. Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman.
Al-Rashdi AA; Sabt BI; Al-Mujaini AS
BMC Ophthalmol; 2022 Dec; 22(1):470. PubMed ID: 36471269
[TBL] [Abstract][Full Text] [Related]
15. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
[TBL] [Abstract][Full Text] [Related]
16. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L
Mult Scler Relat Disord; 2014 Sep; 3(5):629-38. PubMed ID: 26265275
[TBL] [Abstract][Full Text] [Related]
17. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Széplaki G; Merkely B
Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L;
J Neurol; 2014 Feb; 261(2):267-76. PubMed ID: 24221641
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
